94
Views
0
CrossRef citations to date
0
Altmetric
General Medicine

Correlation Between Lipoprotein-Related Phospholipase A2 and Metabolic Syndrome

ORCID Icon, , , , &
Pages 6041-6049 | Received 27 Aug 2023, Accepted 15 Dec 2023, Published online: 21 Dec 2023

References

  • Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci. 1984;81(12):3883–3887.
  • Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2004;26(2):137–144. doi:10.1093/eurheartj/ehi010
  • Kurniawan LB, Rampo H, Soraya GV, et al. Effect of obesity, glucose control, lipid profiles, and blood pressure on Lp-PLA2 levels in type 2 diabetes mellitus patients. Obesity Med. 2021;22:100318. doi:10.1016/j.obmed.2021.100318
  • Jakubiak GK, Osadnik K, Lejawa M, et al. “Obesity and insulin resistance” is the component of the metabolic syndrome most strongly associated with oxidative stress. Antioxidants. 2021;11(1):79. doi:10.3390/antiox11010079
  • Monteiro R, Azevedo I. Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflammation. 2010;2010:1–10. doi:10.1155/2010/289645
  • International diabetes federation: the IDF consensus worldwide definition of the metabolic syndrome. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html. Accessed March 8, 2023.
  • Jackisch L, Kumsaiyai W, Moore JD, et al. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids. Diabetologia. 2018;61(5):1155–1166. doi:10.1007/s00125-018-4558-6
  • Schaefer EJ, McNamara J, Asztalos BF, et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol. 2005;95(9):1025–1032. doi:10.1016/j.amjcard.2005.01.023
  • PLd L, Favarato D, Junior JRF, Lemos P, Chagas ACP. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics. 2008;63(4):427–432. doi:10.1590/S1807-59322008000400003
  • Ren X, Chen Z, Zheng S, et al. Association between Triglyceride to HDL-C Ratio (TG/HDL-C) and insulin resistance in Chinese patients with newly diagnosed type 2 diabetes mellitus. PLoS One. 2016;11(4):e0154345. doi:10.1371/journal.pone.0154345
  • Scicali R, Giral P, D’Erasmo L, et al. High TG to HDL ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes Metab Res Rev. 2021;37(2):e3367. doi:10.1002/dmrr.3367
  • Krawczyk M, Rumińska M, Witkowska- Sędek E, Majcher A, Pyrżak B. Usefulness of the Triglycerides to High-Density Lipoprotein Cholesterol ratio (TG/HDL-C) in prediction of metabolic syndrome in Polish obese children and adolescents. Acta Biochim Pol. 2018;65(4):605–611. doi:10.18388/abp.2018_2649
  • da Silva IT, Timm ADS, Damasceno NR, et al. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis. 2013;12(1):19. doi:10.1186/1476-511X-12-19
  • Chen Y, Li W, Chen Y, et al. The correlation between lipoprotein associated phospholipase A2 and central overweight status. Int J Immunopathol Pharmacol. 2021;35:205873842110485. doi:10.1177/20587384211048562
  • Hsieh SD, Yoshinaga H. Abdominal fat distribution and coronary heart disease risk factors in men-waist/height ratio as a simple and useful predictor. Int J Obes Relat Metab Disord. 1995;19(8):585–589.
  • Rodrigues SL, Baldo MP, Mill JG. Association of waist-stature ratio with hypertension and metabolic syndrome: population-based study. Arq Bras Cardiol. 2010;95(2):186–191. doi:10.1590/S0066-782X2010005000073
  • Nelson TL, Biggs ML, Kizer JR, et al. Lipoprotein-associated phospholipase A2(LP-PLA2) and future risk of type 2 diabetes: results from the cardiovascular health study. J Clin Endocrinol Metab. 2012;97(5):1695–1701. doi:10.1210/jc.2011-3026
  • Gonçalves I, Edsfeldt A, Ko NY, et al. Evidence supporting a key role of LP-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol. 2012;32(6):1505–1512. doi:10.1161/ATVBAHA.112.249854
  • English CJ, Lohning AE, Mayr HL, Jones M, Reidlinger DP. Interrelationships among platelet‐activating factor and lipoprotein‐associated phospholipase A2 activity and traditional cardiovascular risk factors. Biofactors. 2023;49(2):457–471. doi:10.1002/biof.1928
  • Trenti A, Tedesco S, Boscaro C, Trevisi L, Bolego C, Cignarella A. Estrogen, angiogenesis, immunity and cell metabolism: solving the puzzle. IJMS. 2018;19(3):859. doi:10.3390/ijms19030859
  • Yang M, Liu Q, Huang T, et al. Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. Theranostics. 2020;10(24):10874–10891. doi:10.7150/thno.47037
  • Acevedo M, Varleta P, Kramer V, et al. Comparison of lipoprotein-associated phospholipase A2 and high sensitive C-reactive protein as determinants of metabolic syndrome in subjects without coronary heart disease: in search of the best predictor. Int J Endocrinol. 2015;2015:1–7. doi:10.1155/2015/934681